
Glenmark Pharma surges 6% on launching type 2 diabetes drug
Glenmark has launched Zita‐PioMet, India’s first triple fixed-dose combination for high insulin‐resistant type 2 diabetes.
Glenmark has launched Zita‐PioMet, India’s first triple fixed-dose combination for high insulin‐resistant type 2 diabetes.
A majority of pharma stocks reported double digit negative returns, while the overall market (BSE Sensex) delivered a 9% plus return.